Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG (NCT03033992)
Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma or Ependymoma, and Feasibility and Efficacy Trial of Optune in Conjunction With Radiation Therapy for Children With Newly Diagnosed DIPG
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
Who can join: Review the eligibility criteria below.
Location: Phoenix Children's Hospital — Phoenix, Arizona
Age range: 3 Years to 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Phoenix Children's Hospital — Phoenix, Arizona
- Children's Hospital Los Angeles — Los Angeles, California
- Lucile Packard Children's Hospital at Stanford University Medical Center — Palo Alto, California
- Children's Hospital of Colorado — Aurora, Colorado
- Children's National Medical Center — Washington D.C., District of Columbia
- Children's Healthcare of Atlanta — Atlanta, Georgia
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- Baylor College of Medicine — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Malignant Glioma
- A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas — Rochester, Minnesota
- Fitness and Nutrition in Glioma — New York, New York
- D2C7-IT With Atezolizumab for Recurrent Gliomas — Durham, North Carolina
- Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. — Stony Brook, New York
- Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma — Houston, Texas
Explore by condition: All Malignant Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.